000 01661cam  2200373zi 4500
0019.869566
003CaOODSP
00520221107162902
006m     o  d f      
007cr |||||||||||
008190308e201906##onca    o    f000 0 eng d
020 |a9780660299686
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aNR16-264/2019E-PDF
24500|aAdenoviral vectors for vaccines and cancer therapy : |blicensing opportunity L-10890.
264 1|a[Ottawa] : |bNational Research Council Canada = Conseil national de recherches Canada, |cJune 2019.
264 4|c©2019
300 |a1 online resource (2 unnumbered pages) : |bcolour illustrations
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aCaption title.
500 |aIssued also in French under title: Vecteurs adénoviraux pour les vaccins et le traitement du cancer : possibilité d’octroi de licences L-10890.
500 |aIssued also in HTML format.
650 0|aAdenoviruses.
650 0|aVaccines.
650 0|aCancer|xTreatment.
7102 |aNational Research Council Canada, |eissuing body.
77508|tVecteurs adénoviraux pour les vaccins et le traitement du cancer : |w(CaOODSP)9.869568
7760#|tAdenoviral vectors for vaccines and cancer therapy.|w(CaOODSP)9.869567
85640|qPDF|s289 KB|uhttps://publications.gc.ca/collections/collection_2021/cnrc-nrc/NR16-264-2019-eng.pdf
8564 |qHTML|sN/A|uhttps://nrc.canada.ca/en/research-development/intellectual-property-licensing/adenoviral-vectors-vaccines-cancer-therapy-l-10890